Browse the evidence

PWD have greater odds of reporting zero total physical activity compared to PWoD (OR = 5.18, 95 % CI = 2.19-12.24, p < 0.001).

Interventions for PWD should focus on increasing overall physical activity levels.

Adipocyte browning enhances energy expenditure, improves insulin sensitivity, and mitigates lipid accumulation.

Adipocyte browning could be targeted in therapies for obesity and metabolic diseases.

Bariatric surgery is associated with a 42.4% reduction in fat mass (FM) at 6 months, 49.7% at 12 months, and 49.7% at 24 months.

Bariatric surgery significantly reduces fat mass in patients over a 24-month period.

Both bariatric surgery and GLP-1RA treatment improve the fat-free mass (FFM) to fat mass (FM) ratio.

Both interventions are effective in improving body composition ratios.

Patients show a strong commitment to obtaining and maintaining weight-loss medication despite disruptions to their daily lives.

Health care providers should recognize the dedication of patients in managing their weight-loss treatment.

Health care professionals align patients' expectations for immediate weight loss while navigating moral reasoning about weight loss methods.

Practitioners should be aware of the expectations patients have and the ethical considerations in weight-loss discussions.

Recommendations for collaborative action include developing obesity education and care standards that incorporate patients' perspectives.

Healthcare systems should prioritize patient-centered approaches in obesity care.

Emerging therapies for genetic and syndromic obesities include approved treatments like setmelanotide and semaglutide.

Practitioners should consider the use of approved therapies like setmelanotide and semaglutide in treatment plans.

Among 11,700 reports from July 2009 to April 2024, 13 incidents related to GLP-1 agonist use were identified, including seven cases concerning aspiration.

Clinicians should be aware of the potential aspiration risks associated with GLP-1 agonist use in the perioperative setting.

The primary outcome of the RESTART trial is a change in cardiorespiratory fitness (V̇O 2max) at 24 months.

Monitoring changes in cardiorespiratory fitness can be crucial for assessing the effectiveness of lifestyle interventions.

Weight increases of 1.0% to 2.9%, 3.0% to 4.9%, and 5.0% or greater are associated with a higher risk of type 2 diabetes by 15%, 35%, and 51%, respectively.

Weight gain should be avoided to reduce the risk of developing type 2 diabetes.

Faster resistance training tempos may have a trivial advantage over slower tempos for muscle hypertrophy.

Practitioners might consider that while faster tempos could be slightly more beneficial, the difference is not significant.

Subgroup analyses indicate trivial to small effects of resistance training tempo on muscle hypertrophy under specific conditions.

Practitioners should be aware that the effects of tempo may vary based on specific training conditions.

LLM responses had significantly higher scores than internet responses in the 'objectivity' and 'reproducibility' categories.

Practitioners may consider using LLMs for more objective and reproducible information on GLP1RA therapy.

Current therapeutic strategies for obesity include lifestyle interventions, pharmacologic treatments, and bariatric surgery.

Practitioners should consider a multi-faceted approach to obesity treatment.

Community-based lifestyle interventions to manage excess weight can be successfully conducted in Indigenous Australians, but with generally limited efficacy.

Practitioners should consider implementing community-based lifestyle programs, while being aware of their limited effectiveness.

The effect of lifestyle programs on weight reduction was modest (∼2-4 kg after 4-12 months).

Weight loss from lifestyle programs may be limited, and practitioners should set realistic expectations.

Tirzepatide achieves unprecedented weight loss, but case reports suggest potential sexual side effects.

Clinicians should monitor for potential sexual side effects in patients using Tirzepatide for weight loss.

Non-Hispanic Black (NHB) participants had lower percent total weight loss (%TWL) at 3, 12, and 24 months compared with Hispanic (H) and non-Hispanic White (NHW) participants.

Healthcare providers should consider racial and ethnic differences when evaluating weight loss outcomes post-surgery.

Tirzepatide produced meaningful weight loss across groups, but outcomes varied based on weight-reduction status and T2D status.

Practitioners should consider individual patient factors when prescribing tirzepatide for weight loss.

The S3 guideline for the prevention and treatment of obesity includes new recommendations on stigmatization, diagnostics, and therapy, incorporating areas like E-Health.

Practitioners should consider the new recommendations in their approach to obesity treatment.

There are no significant differences in muscle mass and strength gains between consuming protein three or five times a day.

Practitioners can advise that both three and five protein meals are effective for muscle gain.

Adherence to recommended dosage and seeking medical advice regarding possible side effects/interactions is recommended.

Practitioners should advise patients to follow dosage guidelines and consult healthcare providers.

Metabolic bariatric surgery is associated with durable weight loss and lower observed rates of major adverse cardiovascular events (MACE), heart failure, and all-cause mortality compared with non-surgical care.

Practitioners can consider metabolic bariatric surgery as an effective option for achieving weight loss and reducing cardiovascular risks.